[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fRcUJnX3cW5b7w6UhDIek-dAQhKzqg2uMj61HlH6Y-tE":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":85,"rows":92},"Centre hospitalier de l'Université de Montréal (CHUM)",[4],363,false,113,14,121336,32,284,[14,17,20,23,25,28,30,32],{"name":15,"count":16},"Lung Cancer",16,{"name":18,"count":19},"Colorectal Cancer",9,{"name":21,"count":22},"Pain",7,{"name":24,"count":22},"Polyp of Colon",{"name":26,"count":27},"Postoperative Pain",6,{"name":29,"count":27},"Glaucoma",{"name":31,"count":27},"Cancer",{"name":33,"count":27},"Anesthesia",[35,40,45,50,55,60,65,70,75,80],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT03283605","Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas","2024-07-31","Durvalumab",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT04118920","Safety of Topical Insulin Drops for Open-angle Glaucoma","2024-08-20","Topical insulin",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT04951583","Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma","2024-09-01","FMT + ICI",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT05092191","Cannabis as a Complementary Treatment in Multiple Sclerosis","2025-04-10","Cannabis oil vs placebo",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT06923540","Intravenous Acetaminophen to Reduce Post-operative Opioid Consumption","2025-08-15","IV Acetaminophen",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT05806021","The Efficacy of Intra-articular Triamcinolone Acetonide 5mg vs. 10 mg vs. 40 mg in Patients With Knee Osteoarthritis","2025-12","Triamcinolone Acetonide",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT04261478","Endovascular Acute Stroke Intervention - Tandem OCclusion Trial","2026-06","Antiplatelet Agents",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT07248280","Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients","2026-07-01","Aprepitant 40mg",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT06099379","Modulation of THC Effects by CBD: a Dose-ranging Study","2026-07-31","∆9-tetrahydrocannabinol",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT05408065","Comparison of the Analgesic Effect of 2 Shoulder Infiltrations","2026-09","Triamcinolone Hexacetonide and hyaluronic acid",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,118,144,169,201,226,249,275,312,334,356,384,407,434,458,486,509,527,558,576,594,612,637,659,677,703,730,754,783,801,828,851,869,896,921,953,971,997,1023,1048,1072,1090,1115,1140,1166,1184,1210,1228,1252,1276,1302,1320,1348,1366,1384,1402,1420,1445,1471,1497,1521,1546,1564,1590,1614,1639,1666,1689,1718,1745,1763,1787,1814,1839,1883,1911,1949,1982,2011,2034,2052,2077,2100,2118,2136,2161,2179,2204,2222,2248,2266,2289,2314,2339,2357,2382,2408,2431,2457,2479],{"intervention":64,"totalTrials":94,"cells":95},1,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":105,"NA":116},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":98},[],{"trials":106,"activeCount":94,"soonestReadout":63},[107],{"nctId":61,"briefTitle":62,"status":108,"phases":109,"primaryCompletion":63,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":115},"RECRUITING",[90],"2026-02","2024-01-15",327,[114],"Primary Gonarthrosis",[64],{"trials":117,"activeCount":98},[],{"intervention":119,"totalTrials":94,"cells":120},"Intravenous unfractionated heparin",{"EARLY_PHASE1":121,"PHASE1":123,"PHASE2":125,"PHASE3":127,"PHASE4":129,"NA":142},{"trials":122,"activeCount":98},[],{"trials":124,"activeCount":98},[],{"trials":126,"activeCount":98},[],{"trials":128,"activeCount":98},[],{"trials":130,"activeCount":94,"soonestReadout":135},[131],{"nctId":132,"briefTitle":133,"status":108,"phases":134,"primaryCompletion":135,"completion":136,"start":137,"enrollment":138,"conditions":139,"interventions":141},"NCT04725201","Prospective Study on the Role of Intravenous Unfractionated Heparin Following Digital Replantation and Revascularization",[90],"2027-03-01","2027-05-01","2021-05-24",188,[140],"Amputation; Traumatic, Hand",[119],{"trials":143,"activeCount":98},[],{"intervention":145,"totalTrials":94,"cells":146},"N-13 ammonia intravenous",{"EARLY_PHASE1":147,"PHASE1":149,"PHASE2":151,"PHASE3":153,"PHASE4":155,"NA":167},{"trials":148,"activeCount":98},[],{"trials":150,"activeCount":98},[],{"trials":152,"activeCount":98},[],{"trials":154,"activeCount":98},[],{"trials":156,"activeCount":94,"soonestReadout":161},[157],{"nctId":158,"briefTitle":159,"status":108,"phases":160,"primaryCompletion":161,"completion":161,"start":162,"enrollment":163,"conditions":164,"interventions":166},"NCT03275584","Safety of PET MPI Using the CRCHUM N-13 Ammonia",[90],"2028-01","2018-01-30",20000,[165],"N-13 Ammonia Safety",[145],{"trials":168,"activeCount":98},[],{"intervention":59,"totalTrials":94,"cells":170},{"EARLY_PHASE1":171,"PHASE1":173,"PHASE2":175,"PHASE3":177,"PHASE4":179,"NA":199},{"trials":172,"activeCount":98},[],{"trials":174,"activeCount":98},[],{"trials":176,"activeCount":98},[],{"trials":178,"activeCount":98},[],{"trials":180,"activeCount":94,"soonestReadout":58},[181],{"nctId":56,"briefTitle":57,"status":182,"phases":183,"primaryCompletion":58,"completion":58,"start":184,"enrollment":185,"conditions":186,"interventions":198},"NOT_YET_RECRUITING",[90],"2025-04-28",140,[187,188,189,190,191,192,193,194,195,196,197],"Post Operative Analgesia","Opioid Consumption, Postoperative","Acetaminophen","Abdominal Surgeries","Post Operative Bowel Dysfunction","Post Operative Nausea and Vomiting","Post Operative Pain Control","Mobility","Epidural Analgesia","Length of Stay","Pain Management",[59],{"trials":200,"activeCount":98},[],{"intervention":202,"totalTrials":94,"cells":203},"Mepolizumab 100 MG",{"EARLY_PHASE1":204,"PHASE1":206,"PHASE2":208,"PHASE3":210,"PHASE4":212,"NA":224},{"trials":205,"activeCount":98},[],{"trials":207,"activeCount":98},[],{"trials":209,"activeCount":98},[],{"trials":211,"activeCount":98},[],{"trials":213,"activeCount":94,"soonestReadout":218},[214],{"nctId":215,"briefTitle":216,"status":108,"phases":217,"primaryCompletion":218,"completion":218,"start":219,"enrollment":220,"conditions":221,"interventions":223},"NCT05902325","Identifying Predictors Of Response To Mepolizumab In CRSwNP",[90],"2026-12-31","2023-10-03",36,[222],"Chronic Rhinosinusitis With Nasal Polyps",[202],{"trials":225,"activeCount":98},[],{"intervention":74,"totalTrials":94,"cells":227},{"EARLY_PHASE1":228,"PHASE1":230,"PHASE2":232,"PHASE3":234,"PHASE4":245,"NA":247},{"trials":229,"activeCount":98},[],{"trials":231,"activeCount":98},[],{"trials":233,"activeCount":98},[],{"trials":235,"activeCount":94,"soonestReadout":73},[236],{"nctId":71,"briefTitle":72,"status":108,"phases":237,"primaryCompletion":73,"completion":238,"start":239,"enrollment":240,"conditions":241,"interventions":244},[89],"2027-01-01","2026-02-27",260,[242,243],"Nausea and Vomiting, Postoperative","Prevention",[74],{"trials":246,"activeCount":98},[],{"trials":248,"activeCount":98},[],{"intervention":250,"totalTrials":94,"cells":251},"F-choline intravenous",{"EARLY_PHASE1":252,"PHASE1":254,"PHASE2":256,"PHASE3":258,"PHASE4":271,"NA":273},{"trials":253,"activeCount":98},[],{"trials":255,"activeCount":98},[],{"trials":257,"activeCount":98},[],{"trials":259,"activeCount":94,"soonestReadout":264},[260],{"nctId":261,"briefTitle":262,"status":108,"phases":263,"primaryCompletion":264,"completion":265,"start":266,"enrollment":267,"conditions":268,"interventions":270},"NCT04999215","Choline-PET: Exploratory Study Assessing the Potential Role of F-choline PET Imaging in New and Emerging Indications",[89],"2032-07-01","2032-08-01","2022-08-01",500,[269],"Lesion With Known or Suspected F-choline Uptake",[250],{"trials":272,"activeCount":98},[],{"trials":274,"activeCount":98},[],{"intervention":276,"totalTrials":277,"cells":278},"Topical Infliximab",2,{"EARLY_PHASE1":279,"PHASE1":281,"PHASE2":293,"PHASE3":306,"PHASE4":308,"NA":310},{"trials":280,"activeCount":98},[],{"trials":282,"activeCount":98},[283],{"nctId":284,"briefTitle":285,"status":286,"phases":287,"primaryCompletion":288,"completion":288,"start":289,"enrollment":22,"conditions":290,"interventions":292},"NCT02987686","Topical Infliximab for Sterile Corneal Melt","COMPLETED",[87],"2025-11-15","2017-09-06",[291],"Sterile Corneal Melt",[276],{"trials":294,"activeCount":94,"soonestReadout":135},[295],{"nctId":296,"briefTitle":297,"status":108,"phases":298,"primaryCompletion":135,"completion":299,"start":300,"enrollment":301,"conditions":302,"interventions":304},"NCT05180994","Topical Infliximab in Eyes With Penetrating Keratoplasty",[87,88],"2028-03-01","2022-05-01",50,[303],"Glaucoma Following Surgery",[305],"Topical infliximab",{"trials":307,"activeCount":98},[],{"trials":309,"activeCount":98},[],{"trials":311,"activeCount":98},[],{"intervention":54,"totalTrials":94,"cells":313},{"EARLY_PHASE1":314,"PHASE1":316,"PHASE2":318,"PHASE3":328,"PHASE4":330,"NA":332},{"trials":315,"activeCount":98},[],{"trials":317,"activeCount":98},[],{"trials":319,"activeCount":94,"soonestReadout":53},[320],{"nctId":51,"briefTitle":52,"status":108,"phases":321,"primaryCompletion":53,"completion":322,"start":323,"enrollment":324,"conditions":325,"interventions":327},[88],"2025-05-10","2022-11-10",250,[326],"Multiple Sclerosis",[54],{"trials":329,"activeCount":98},[],{"trials":331,"activeCount":98},[],{"trials":333,"activeCount":98},[],{"intervention":79,"totalTrials":94,"cells":335},{"EARLY_PHASE1":336,"PHASE1":338,"PHASE2":340,"PHASE3":350,"PHASE4":352,"NA":354},{"trials":337,"activeCount":98},[],{"trials":339,"activeCount":98},[],{"trials":341,"activeCount":94,"soonestReadout":78},[342],{"nctId":76,"briefTitle":77,"status":108,"phases":343,"primaryCompletion":78,"completion":218,"start":344,"enrollment":345,"conditions":346,"interventions":349},[87,88],"2024-06-27",100,[347,348],"Cannabis","THC",[79],{"trials":351,"activeCount":98},[],{"trials":353,"activeCount":98},[],{"trials":355,"activeCount":98},[],{"intervention":357,"totalTrials":94,"cells":358},"Trazodone 25 mg",{"EARLY_PHASE1":359,"PHASE1":361,"PHASE2":363,"PHASE3":378,"PHASE4":380,"NA":382},{"trials":360,"activeCount":98},[],{"trials":362,"activeCount":98},[],{"trials":364,"activeCount":94,"soonestReadout":369},[365],{"nctId":366,"briefTitle":367,"status":108,"phases":368,"primaryCompletion":369,"completion":370,"start":371,"enrollment":372,"conditions":373,"interventions":377},"NCT06983080","Efficacy of Trazodone to Treat Insomnia in Older Adults (TRADITION Study)",[88],"2027-07","2027-12","2025-11-10",40,[374,375,376],"Insomnia Chronic","Older People","Drug Therapy",[357],{"trials":379,"activeCount":98},[],{"trials":381,"activeCount":98},[],{"trials":383,"activeCount":98},[],{"intervention":385,"totalTrials":94,"cells":386},"Cannabis, placebo",{"EARLY_PHASE1":387,"PHASE1":389,"PHASE2":391,"PHASE3":401,"PHASE4":403,"NA":405},{"trials":388,"activeCount":98},[],{"trials":390,"activeCount":98},[],{"trials":392,"activeCount":94,"soonestReadout":397},[393],{"nctId":394,"briefTitle":395,"status":182,"phases":396,"primaryCompletion":397,"completion":370,"start":83,"enrollment":398,"conditions":399,"interventions":400},"NCT05320367","A Study of Inhaled Cannabidiol in Healthy Occasional Cannabis Users",[87,88],"2027-10",80,[347],[385],{"trials":402,"activeCount":98},[],{"trials":404,"activeCount":98},[],{"trials":406,"activeCount":98},[],{"intervention":408,"totalTrials":94,"cells":409},"Fostemsavir",{"EARLY_PHASE1":410,"PHASE1":412,"PHASE2":414,"PHASE3":428,"PHASE4":430,"NA":432},{"trials":411,"activeCount":98},[],{"trials":413,"activeCount":98},[],{"trials":415,"activeCount":94,"soonestReadout":420},[416],{"nctId":417,"briefTitle":418,"status":108,"phases":419,"primaryCompletion":420,"completion":421,"start":422,"enrollment":423,"conditions":424,"interventions":427},"NCT07030920","Reducing Systemic Inflammation in People on Antiretroviral Therapy",[88],"2028-10","2029-01","2025-09-30",150,[425,426],"Human Immunodeficiency Virus (HIV)","Cardiovascular Risk Factor",[408],{"trials":429,"activeCount":98},[],{"trials":431,"activeCount":98},[],{"trials":433,"activeCount":98},[],{"intervention":49,"totalTrials":94,"cells":435},{"EARLY_PHASE1":436,"PHASE1":438,"PHASE2":440,"PHASE3":452,"PHASE4":454,"NA":456},{"trials":437,"activeCount":98},[],{"trials":439,"activeCount":98},[],{"trials":441,"activeCount":94,"soonestReadout":48},[442],{"nctId":46,"briefTitle":47,"status":443,"phases":444,"primaryCompletion":48,"completion":445,"start":446,"enrollment":447,"conditions":448,"interventions":451},"ACTIVE_NOT_RECRUITING",[88],"2025-09-01","2021-11-16",45,[449,450],"Non Small Cell Lung Cancer Metastatic","Advanced Melanoma",[49],{"trials":453,"activeCount":98},[],{"trials":455,"activeCount":98},[],{"trials":457,"activeCount":98},[],{"intervention":459,"totalTrials":94,"cells":460},"Mycophenolate Mofetil",{"EARLY_PHASE1":461,"PHASE1":463,"PHASE2":465,"PHASE3":480,"PHASE4":482,"NA":484},{"trials":462,"activeCount":98},[],{"trials":464,"activeCount":98},[],{"trials":466,"activeCount":94,"soonestReadout":471},[467],{"nctId":468,"briefTitle":469,"status":108,"phases":470,"primaryCompletion":471,"completion":472,"start":473,"enrollment":474,"conditions":475,"interventions":479},"NCT05785065","Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease",[88],"2026-12","2028-12","2024-08-29",35,[476,477,478],"Systemic Sclerosis With Lung Involvement","Systemic Sclerosis","Interstitial Lung Disease",[459],{"trials":481,"activeCount":98},[],{"trials":483,"activeCount":98},[],{"trials":485,"activeCount":98},[],{"intervention":39,"totalTrials":94,"cells":487},{"EARLY_PHASE1":488,"PHASE1":490,"PHASE2":492,"PHASE3":503,"PHASE4":505,"NA":507},{"trials":489,"activeCount":98},[],{"trials":491,"activeCount":98},[],{"trials":493,"activeCount":94,"soonestReadout":38},[494],{"nctId":36,"briefTitle":37,"status":443,"phases":495,"primaryCompletion":38,"completion":496,"start":497,"enrollment":447,"conditions":498,"interventions":501},[87,88],"2024-12-31","2018-07-17",[499,500],"Head and Neck Squamous Cell Carcinoma","Metastatic Squamous Cell Carcinoma",[39,502],"Tremelimumab",{"trials":504,"activeCount":98},[],{"trials":506,"activeCount":98},[],{"trials":508,"activeCount":98},[],{"intervention":502,"totalTrials":94,"cells":510},{"EARLY_PHASE1":511,"PHASE1":513,"PHASE2":515,"PHASE3":521,"PHASE4":523,"NA":525},{"trials":512,"activeCount":98},[],{"trials":514,"activeCount":98},[],{"trials":516,"activeCount":94,"soonestReadout":38},[517],{"nctId":36,"briefTitle":37,"status":443,"phases":518,"primaryCompletion":38,"completion":496,"start":497,"enrollment":447,"conditions":519,"interventions":520},[87,88],[499,500],[39,502],{"trials":522,"activeCount":98},[],{"trials":524,"activeCount":98},[],{"trials":526,"activeCount":98},[],{"intervention":528,"totalTrials":94,"cells":529},"Treatment as Usual plus Placebo",{"EARLY_PHASE1":530,"PHASE1":532,"PHASE2":534,"PHASE3":552,"PHASE4":554,"NA":556},{"trials":531,"activeCount":98},[],{"trials":533,"activeCount":98},[],{"trials":535,"activeCount":94,"soonestReadout":370},[536],{"nctId":537,"briefTitle":538,"status":108,"phases":539,"primaryCompletion":370,"completion":540,"start":541,"enrollment":542,"conditions":543,"interventions":548},"NCT05854667","Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users",[88],"2028-04","2023-12-05",440,[544,545,546,547],"Methamphetamine Abuse","Methamphetamine-dependence","Addiction, Substance","Addiction",[528,549,550,551],"Treatment as Usual plus Placebo plus Contingency Management","Treatment as Usual plus lisdexamfetamine","Treatment as Usual plus lisdexamfetamine (LDX-01) plus Contingency Management",{"trials":553,"activeCount":98},[],{"trials":555,"activeCount":98},[],{"trials":557,"activeCount":98},[],{"intervention":549,"totalTrials":94,"cells":559},{"EARLY_PHASE1":560,"PHASE1":562,"PHASE2":564,"PHASE3":570,"PHASE4":572,"NA":574},{"trials":561,"activeCount":98},[],{"trials":563,"activeCount":98},[],{"trials":565,"activeCount":94,"soonestReadout":370},[566],{"nctId":537,"briefTitle":538,"status":108,"phases":567,"primaryCompletion":370,"completion":540,"start":541,"enrollment":542,"conditions":568,"interventions":569},[88],[544,545,546,547],[528,549,550,551],{"trials":571,"activeCount":98},[],{"trials":573,"activeCount":98},[],{"trials":575,"activeCount":98},[],{"intervention":550,"totalTrials":94,"cells":577},{"EARLY_PHASE1":578,"PHASE1":580,"PHASE2":582,"PHASE3":588,"PHASE4":590,"NA":592},{"trials":579,"activeCount":98},[],{"trials":581,"activeCount":98},[],{"trials":583,"activeCount":94,"soonestReadout":370},[584],{"nctId":537,"briefTitle":538,"status":108,"phases":585,"primaryCompletion":370,"completion":540,"start":541,"enrollment":542,"conditions":586,"interventions":587},[88],[544,545,546,547],[528,549,550,551],{"trials":589,"activeCount":98},[],{"trials":591,"activeCount":98},[],{"trials":593,"activeCount":98},[],{"intervention":551,"totalTrials":94,"cells":595},{"EARLY_PHASE1":596,"PHASE1":598,"PHASE2":600,"PHASE3":606,"PHASE4":608,"NA":610},{"trials":597,"activeCount":98},[],{"trials":599,"activeCount":98},[],{"trials":601,"activeCount":94,"soonestReadout":370},[602],{"nctId":537,"briefTitle":538,"status":108,"phases":603,"primaryCompletion":370,"completion":540,"start":541,"enrollment":542,"conditions":604,"interventions":605},[88],[544,545,546,547],[528,549,550,551],{"trials":607,"activeCount":98},[],{"trials":609,"activeCount":98},[],{"trials":611,"activeCount":98},[],{"intervention":613,"totalTrials":94,"cells":614},"LDX-01 plus TAU",{"EARLY_PHASE1":615,"PHASE1":617,"PHASE2":619,"PHASE3":631,"PHASE4":633,"NA":635},{"trials":616,"activeCount":98},[],{"trials":618,"activeCount":98},[],{"trials":620,"activeCount":94,"soonestReadout":625},[621],{"nctId":622,"briefTitle":623,"status":108,"phases":624,"primaryCompletion":625,"completion":370,"start":626,"enrollment":398,"conditions":627,"interventions":630},"NCT06788587","Feasibility of Long-term, High-dose Stimulant for Methamphetamine Use Disorder",[88],"2027-08","2025-07-18",[544,545,547,628,629],"Substance Abuse","Methamphetamine Use Disorder",[613],{"trials":632,"activeCount":98},[],{"trials":634,"activeCount":98},[],{"trials":636,"activeCount":98},[],{"intervention":44,"totalTrials":94,"cells":638},{"EARLY_PHASE1":639,"PHASE1":641,"PHASE2":651,"PHASE3":653,"PHASE4":655,"NA":657},{"trials":640,"activeCount":98},[],{"trials":642,"activeCount":94,"soonestReadout":43},[643],{"nctId":41,"briefTitle":42,"status":443,"phases":644,"primaryCompletion":43,"completion":645,"start":646,"enrollment":647,"conditions":648,"interventions":649},[87],"2024-12","2023-03-27",18,[29],[44,44,650],"Artificial tears",{"trials":652,"activeCount":98},[],{"trials":654,"activeCount":98},[],{"trials":656,"activeCount":98},[],{"trials":658,"activeCount":98},[],{"intervention":650,"totalTrials":94,"cells":660},{"EARLY_PHASE1":661,"PHASE1":663,"PHASE2":669,"PHASE3":671,"PHASE4":673,"NA":675},{"trials":662,"activeCount":98},[],{"trials":664,"activeCount":94,"soonestReadout":43},[665],{"nctId":41,"briefTitle":42,"status":443,"phases":666,"primaryCompletion":43,"completion":645,"start":646,"enrollment":647,"conditions":667,"interventions":668},[87],[29],[44,44,650],{"trials":670,"activeCount":98},[],{"trials":672,"activeCount":98},[],{"trials":674,"activeCount":98},[],{"trials":676,"activeCount":98},[],{"intervention":678,"totalTrials":94,"cells":679},"PEGLyte bowel preparation",{"EARLY_PHASE1":680,"PHASE1":682,"PHASE2":695,"PHASE3":697,"PHASE4":699,"NA":701},{"trials":681,"activeCount":98},[],{"trials":683,"activeCount":94,"soonestReadout":688},[684],{"nctId":685,"briefTitle":686,"status":108,"phases":687,"primaryCompletion":688,"completion":689,"start":690,"enrollment":691,"conditions":692,"interventions":694},"NCT06831539","Impact of PEG Bowel Preparation on Gut Microbiome Composition Recovery",[87],"2026-09-01","2026-12-05","2024-12-05",20,[31,693],"Healthy Participants",[678],{"trials":696,"activeCount":98},[],{"trials":698,"activeCount":98},[],{"trials":700,"activeCount":98},[],{"trials":702,"activeCount":98},[],{"intervention":704,"totalTrials":94,"cells":705},"KAN-004",{"EARLY_PHASE1":706,"PHASE1":708,"PHASE2":722,"PHASE3":724,"PHASE4":726,"NA":728},{"trials":707,"activeCount":98},[],{"trials":709,"activeCount":94,"soonestReadout":714},[710],{"nctId":711,"briefTitle":712,"status":108,"phases":713,"primaryCompletion":714,"completion":715,"start":716,"enrollment":717,"conditions":718,"interventions":721},"NCT07196410","KAN-004 for Immune-Related Diarrhea or Colitis",[87],"2028-12-31","2030-12-31","2026-03-01",21,[719,720],"Colitis","Diarrhea Caused by Antitumor Drugs",[704],{"trials":723,"activeCount":98},[],{"trials":725,"activeCount":98},[],{"trials":727,"activeCount":98},[],{"trials":729,"activeCount":98},[],{"intervention":69,"totalTrials":94,"cells":731},{"EARLY_PHASE1":732,"PHASE1":734,"PHASE2":736,"PHASE3":738,"PHASE4":740,"NA":742},{"trials":733,"activeCount":98},[],{"trials":735,"activeCount":98},[],{"trials":737,"activeCount":98},[],{"trials":739,"activeCount":98},[],{"trials":741,"activeCount":98},[],{"trials":743,"activeCount":94,"soonestReadout":68},[744],{"nctId":66,"briefTitle":67,"status":108,"phases":745,"primaryCompletion":68,"completion":746,"start":747,"enrollment":748,"conditions":749,"interventions":753},[91],"2027-03","2020-08-31",458,[750,751,752],"Stroke, Acute","Carotid Stenosis","Carotid Artery Diseases",[69],{"intervention":755,"totalTrials":94,"cells":756},"Cemiplimab",{"EARLY_PHASE1":757,"PHASE1":759,"PHASE2":761,"PHASE3":763,"PHASE4":765,"NA":767},{"trials":758,"activeCount":98},[],{"trials":760,"activeCount":98},[],{"trials":762,"activeCount":98},[],{"trials":764,"activeCount":98},[],{"trials":766,"activeCount":98},[],{"trials":768,"activeCount":94,"soonestReadout":773},[769],{"nctId":770,"briefTitle":771,"status":182,"phases":772,"primaryCompletion":773,"completion":774,"start":775,"enrollment":776,"conditions":777,"interventions":781},"NCT06743581","Phase I\u002FII Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer",[91],"2027-02","2030-02","2025-02-01",24,[778,779,780],"Non-Small Cell Lung Cancer","Immunotherapy","Neoadjuvant Therapy",[755,782],"Dupilumab",{"intervention":782,"totalTrials":94,"cells":784},{"EARLY_PHASE1":785,"PHASE1":787,"PHASE2":789,"PHASE3":791,"PHASE4":793,"NA":795},{"trials":786,"activeCount":98},[],{"trials":788,"activeCount":98},[],{"trials":790,"activeCount":98},[],{"trials":792,"activeCount":98},[],{"trials":794,"activeCount":98},[],{"trials":796,"activeCount":94,"soonestReadout":773},[797],{"nctId":770,"briefTitle":771,"status":182,"phases":798,"primaryCompletion":773,"completion":774,"start":775,"enrollment":776,"conditions":799,"interventions":800},[91],[778,779,780],[755,782],{"intervention":802,"totalTrials":94,"cells":803},"Ketamine",{"EARLY_PHASE1":804,"PHASE1":806,"PHASE2":808,"PHASE3":810,"PHASE4":812,"NA":814},{"trials":805,"activeCount":98},[],{"trials":807,"activeCount":98},[],{"trials":809,"activeCount":98},[],{"trials":811,"activeCount":98},[],{"trials":813,"activeCount":98},[],{"trials":815,"activeCount":94,"soonestReadout":820},[816],{"nctId":817,"briefTitle":818,"status":108,"phases":819,"primaryCompletion":820,"completion":821,"start":822,"enrollment":823,"conditions":824,"interventions":827},"NCT06620276","ACT_for Alcohol Use Disorder and Depression",[91],"2026-12-01","2028-06-01","2025-05-01",30,[825,826],"Depression - Major Depressive Disorder","Alcohol Use Disorder",[802],{"intervention":84,"totalTrials":94,"cells":829},{"EARLY_PHASE1":830,"PHASE1":832,"PHASE2":834,"PHASE3":836,"PHASE4":838,"NA":840},{"trials":831,"activeCount":98},[],{"trials":833,"activeCount":98},[],{"trials":835,"activeCount":98},[],{"trials":837,"activeCount":98},[],{"trials":839,"activeCount":98},[],{"trials":841,"activeCount":94,"soonestReadout":83},[842],{"nctId":81,"briefTitle":82,"status":108,"phases":843,"primaryCompletion":83,"completion":471,"start":844,"enrollment":845,"conditions":846,"interventions":849},[91],"2022-11-15",84,[847,848],"Infiltration","Shoulder Osteoarthritis",[84,850],"Triamcinolone Hexacetonide",{"intervention":850,"totalTrials":94,"cells":852},{"EARLY_PHASE1":853,"PHASE1":855,"PHASE2":857,"PHASE3":859,"PHASE4":861,"NA":863},{"trials":854,"activeCount":98},[],{"trials":856,"activeCount":98},[],{"trials":858,"activeCount":98},[],{"trials":860,"activeCount":98},[],{"trials":862,"activeCount":98},[],{"trials":864,"activeCount":94,"soonestReadout":83},[865],{"nctId":81,"briefTitle":82,"status":108,"phases":866,"primaryCompletion":83,"completion":471,"start":844,"enrollment":845,"conditions":867,"interventions":868},[91],[847,848],[84,850],{"intervention":870,"totalTrials":94,"cells":871},"Azithromycin",{"EARLY_PHASE1":872,"PHASE1":874,"PHASE2":876,"PHASE3":878,"PHASE4":880,"NA":894},{"trials":873,"activeCount":98},[],{"trials":875,"activeCount":98},[],{"trials":877,"activeCount":98},[],{"trials":879,"activeCount":98},[],{"trials":881,"activeCount":98},[882],{"nctId":883,"briefTitle":884,"status":286,"phases":885,"primaryCompletion":886,"completion":887,"start":888,"enrollment":889,"conditions":890,"interventions":893},"NCT02307825","Azithromycin for Patients With Chronic Rhinosinusitis Failing Medical and Surgical Therapy",[90],"2017-08-15","2017-12-31","2014-11",129,[891,892],"Chronic Rhinosinusitis","High-risk Patient",[870],{"trials":895,"activeCount":98},[],{"intervention":897,"totalTrials":94,"cells":898},"Intervention\u002FTreatment",{"EARLY_PHASE1":899,"PHASE1":901,"PHASE2":903,"PHASE3":905,"PHASE4":907,"NA":919},{"trials":900,"activeCount":98},[],{"trials":902,"activeCount":98},[],{"trials":904,"activeCount":98},[],{"trials":906,"activeCount":98},[],{"trials":908,"activeCount":98},[909],{"nctId":910,"briefTitle":911,"status":912,"phases":913,"primaryCompletion":914,"completion":914,"start":915,"enrollment":22,"conditions":916,"interventions":918},"NCT06131580","Canadian Continuation of Roll-over Study in Patients With Endogenous Cushing's Syndrome","UNKNOWN",[90],"2025-11-24","2023-10-24",[917],"Endogenous Cushing Syndrome",[897],{"trials":920,"activeCount":98},[],{"intervention":922,"totalTrials":94,"cells":923},"Trazodone",{"EARLY_PHASE1":924,"PHASE1":926,"PHASE2":928,"PHASE3":930,"PHASE4":932,"NA":951},{"trials":925,"activeCount":98},[],{"trials":927,"activeCount":98},[],{"trials":929,"activeCount":98},[],{"trials":931,"activeCount":98},[],{"trials":933,"activeCount":98},[934],{"nctId":935,"briefTitle":936,"status":937,"phases":938,"primaryCompletion":939,"completion":939,"start":940,"enrollment":941,"conditions":942,"interventions":948},"NCT03522207","Accuracy and Efficacy of Trazodone (Desyrel) on Sleep Quality and Pain Management of TMD Patient","TERMINATED",[90],"2020-01-20","2018-10-15",3,[943,944,945,946,947],"TMD","Sleep Bruxism","TMJ Pain","Chronic Pain","Sleep Disorder",[922,949,922,950],"Placebos","placebos",{"trials":952,"activeCount":98},[],{"intervention":949,"totalTrials":94,"cells":954},{"EARLY_PHASE1":955,"PHASE1":957,"PHASE2":959,"PHASE3":961,"PHASE4":963,"NA":969},{"trials":956,"activeCount":98},[],{"trials":958,"activeCount":98},[],{"trials":960,"activeCount":98},[],{"trials":962,"activeCount":98},[],{"trials":964,"activeCount":98},[965],{"nctId":935,"briefTitle":936,"status":937,"phases":966,"primaryCompletion":939,"completion":939,"start":940,"enrollment":941,"conditions":967,"interventions":968},[90],[943,944,945,946,947],[922,949,922,950],{"trials":970,"activeCount":98},[],{"intervention":972,"totalTrials":94,"cells":973},"Desvenlafaxine",{"EARLY_PHASE1":974,"PHASE1":976,"PHASE2":978,"PHASE3":980,"PHASE4":982,"NA":995},{"trials":975,"activeCount":98},[],{"trials":977,"activeCount":98},[],{"trials":979,"activeCount":98},[],{"trials":981,"activeCount":98},[],{"trials":983,"activeCount":98},[984],{"nctId":985,"briefTitle":986,"status":286,"phases":987,"primaryCompletion":988,"completion":988,"start":989,"enrollment":647,"conditions":990,"interventions":994},"NCT02200406","Desvenlafaxine in Opioid-Dependent Patients",[90],"2017-01","2014-07",[991,992,993],"Depression","Opioid Dependence","Methadone Treatment",[972],{"trials":996,"activeCount":98},[],{"intervention":998,"totalTrials":94,"cells":999},"5% human albumin solution",{"EARLY_PHASE1":1000,"PHASE1":1002,"PHASE2":1004,"PHASE3":1006,"PHASE4":1008,"NA":1021},{"trials":1001,"activeCount":98},[],{"trials":1003,"activeCount":98},[],{"trials":1005,"activeCount":98},[],{"trials":1007,"activeCount":98},[],{"trials":1009,"activeCount":98},[1010],{"nctId":1011,"briefTitle":1012,"status":1013,"phases":1014,"primaryCompletion":1015,"completion":1016,"start":1017,"enrollment":98,"conditions":1018,"interventions":1020},"NCT01436292","Hypoalbuminemia in Burn Patients","WITHDRAWN",[90],"2015-09","2015-10","2011-09",[1019],"Second or Third Degree Burns",[998],{"trials":1022,"activeCount":98},[],{"intervention":1024,"totalTrials":94,"cells":1025},"Citalopram",{"EARLY_PHASE1":1026,"PHASE1":1028,"PHASE2":1030,"PHASE3":1032,"PHASE4":1034,"NA":1046},{"trials":1027,"activeCount":98},[],{"trials":1029,"activeCount":98},[],{"trials":1031,"activeCount":98},[],{"trials":1033,"activeCount":98},[],{"trials":1035,"activeCount":98},[1036],{"nctId":1037,"briefTitle":1038,"status":937,"phases":1039,"primaryCompletion":1040,"completion":1040,"start":1041,"enrollment":22,"conditions":1042,"interventions":1045},"NCT01099592","Antidepressants to Promote Recovery of Cardiac Patients Suffering From Depression",[90],"2011-04","2010-11",[1043,1044],"Acute Coronary Syndrome","Major Depressive Episode",[1024],{"trials":1047,"activeCount":98},[],{"intervention":1049,"totalTrials":94,"cells":1050},"Dupilumab 300 MG in 2 ML Prefilled Syringe",{"EARLY_PHASE1":1051,"PHASE1":1053,"PHASE2":1055,"PHASE3":1057,"PHASE4":1059,"NA":1070},{"trials":1052,"activeCount":98},[],{"trials":1054,"activeCount":98},[],{"trials":1056,"activeCount":98},[],{"trials":1058,"activeCount":98},[],{"trials":1060,"activeCount":98},[1061],{"nctId":1062,"briefTitle":1063,"status":286,"phases":1064,"primaryCompletion":1065,"completion":1065,"start":1066,"enrollment":823,"conditions":1067,"interventions":1068},"NCT04596189","Dupilumab for Prevention of Recurrence of CRSwNP After ESS",[90],"2024-04-23","2021-05-25",[222],[1049,1069],"Mometasone Furoate nasal spray",{"trials":1071,"activeCount":98},[],{"intervention":1069,"totalTrials":94,"cells":1073},{"EARLY_PHASE1":1074,"PHASE1":1076,"PHASE2":1078,"PHASE3":1080,"PHASE4":1082,"NA":1088},{"trials":1075,"activeCount":98},[],{"trials":1077,"activeCount":98},[],{"trials":1079,"activeCount":98},[],{"trials":1081,"activeCount":98},[],{"trials":1083,"activeCount":98},[1084],{"nctId":1062,"briefTitle":1063,"status":286,"phases":1085,"primaryCompletion":1065,"completion":1065,"start":1066,"enrollment":823,"conditions":1086,"interventions":1087},[90],[222],[1049,1069],{"trials":1089,"activeCount":98},[],{"intervention":1091,"totalTrials":94,"cells":1092},"Clopidogrel, Prasugrel, Ticagrelor",{"EARLY_PHASE1":1093,"PHASE1":1095,"PHASE2":1097,"PHASE3":1099,"PHASE4":1101,"NA":1113},{"trials":1094,"activeCount":98},[],{"trials":1096,"activeCount":98},[],{"trials":1098,"activeCount":98},[],{"trials":1100,"activeCount":98},[],{"trials":1102,"activeCount":98},[1103],{"nctId":1104,"briefTitle":1105,"status":1013,"phases":1106,"primaryCompletion":1107,"completion":1108,"start":1109,"enrollment":98,"conditions":1110,"interventions":1112},"NCT02302508","Pharmacokinetics of Antiplatelet Drugs in Diabetic pAtients",[90],"2020-12","2021-12","2019-09-01",[1111],"Diabetes",[1091],{"trials":1114,"activeCount":98},[],{"intervention":1116,"totalTrials":94,"cells":1117},"CRCHUM-MT cocktail",{"EARLY_PHASE1":1118,"PHASE1":1120,"PHASE2":1122,"PHASE3":1124,"PHASE4":1126,"NA":1138},{"trials":1119,"activeCount":98},[],{"trials":1121,"activeCount":98},[],{"trials":1123,"activeCount":98},[],{"trials":1125,"activeCount":98},[],{"trials":1127,"activeCount":98},[1128],{"nctId":1129,"briefTitle":1130,"status":286,"phases":1131,"primaryCompletion":1132,"completion":1132,"start":1133,"enrollment":1134,"conditions":1135,"interventions":1137},"NCT02291666","Evaluation of CYP450 Activities in Diabetic Patients vs. Non-diabetic Subjects",[90],"2019-07","2015-04",73,[1136],"Type 2 Diabetes",[1116],{"trials":1139,"activeCount":98},[],{"intervention":1141,"totalTrials":94,"cells":1142},"Quetiapine",{"EARLY_PHASE1":1143,"PHASE1":1145,"PHASE2":1147,"PHASE3":1149,"PHASE4":1162,"NA":1164},{"trials":1144,"activeCount":98},[],{"trials":1146,"activeCount":98},[],{"trials":1148,"activeCount":98},[],{"trials":1150,"activeCount":98},[1151],{"nctId":1152,"briefTitle":1153,"status":286,"phases":1154,"primaryCompletion":1155,"completion":1155,"start":1156,"enrollment":1157,"conditions":1158,"interventions":1160},"NCT01811459","Trial Comparing Haloperidol, Quetiapine and Placebo in the Pharmacological Treatment of Delirium",[89],"2016-09","2013-02",107,[1159],"Delirium",[1141,1161],"Haloperidol",{"trials":1163,"activeCount":98},[],{"trials":1165,"activeCount":98},[],{"intervention":1161,"totalTrials":94,"cells":1167},{"EARLY_PHASE1":1168,"PHASE1":1170,"PHASE2":1172,"PHASE3":1174,"PHASE4":1180,"NA":1182},{"trials":1169,"activeCount":98},[],{"trials":1171,"activeCount":98},[],{"trials":1173,"activeCount":98},[],{"trials":1175,"activeCount":98},[1176],{"nctId":1152,"briefTitle":1153,"status":286,"phases":1177,"primaryCompletion":1155,"completion":1155,"start":1156,"enrollment":1157,"conditions":1178,"interventions":1179},[89],[1159],[1141,1161],{"trials":1181,"activeCount":98},[],{"trials":1183,"activeCount":98},[],{"intervention":1185,"totalTrials":94,"cells":1186},"Saline spray",{"EARLY_PHASE1":1187,"PHASE1":1189,"PHASE2":1191,"PHASE3":1193,"PHASE4":1206,"NA":1208},{"trials":1188,"activeCount":98},[],{"trials":1190,"activeCount":98},[],{"trials":1192,"activeCount":98},[],{"trials":1194,"activeCount":98},[1195],{"nctId":1196,"briefTitle":1197,"status":286,"phases":1198,"primaryCompletion":1199,"completion":1199,"start":1200,"enrollment":1201,"conditions":1202,"interventions":1204},"NCT03967197","Lidocaine Before Esophageal Manometry and Ambulatory pH Monitoring",[88,89],"2020-08-05","2019-08-06",304,[1203],"Pain, Acute",[1185,1205],"Lidocaine Hydrochloride",{"trials":1207,"activeCount":98},[],{"trials":1209,"activeCount":98},[],{"intervention":1205,"totalTrials":94,"cells":1211},{"EARLY_PHASE1":1212,"PHASE1":1214,"PHASE2":1216,"PHASE3":1218,"PHASE4":1224,"NA":1226},{"trials":1213,"activeCount":98},[],{"trials":1215,"activeCount":98},[],{"trials":1217,"activeCount":98},[],{"trials":1219,"activeCount":98},[1220],{"nctId":1196,"briefTitle":1197,"status":286,"phases":1221,"primaryCompletion":1199,"completion":1199,"start":1200,"enrollment":1201,"conditions":1222,"interventions":1223},[88,89],[1203],[1185,1205],{"trials":1225,"activeCount":98},[],{"trials":1227,"activeCount":98},[],{"intervention":1229,"totalTrials":94,"cells":1230},"bosentan",{"EARLY_PHASE1":1231,"PHASE1":1233,"PHASE2":1235,"PHASE3":1237,"PHASE4":1248,"NA":1250},{"trials":1232,"activeCount":98},[],{"trials":1234,"activeCount":98},[],{"trials":1236,"activeCount":98},[],{"trials":1238,"activeCount":98},[1239],{"nctId":1240,"briefTitle":1241,"status":937,"phases":1242,"primaryCompletion":1243,"completion":1244,"start":1245,"enrollment":94,"conditions":1246,"interventions":1247},"NCT00638131","Bosentan Use in Patients With Diabetic Nephropathy",[89],"2010-03","2010-06","2009-01",[1136],[1229],{"trials":1249,"activeCount":98},[],{"trials":1251,"activeCount":98},[],{"intervention":1253,"totalTrials":94,"cells":1254},"EUS procedure with drug",{"EARLY_PHASE1":1255,"PHASE1":1257,"PHASE2":1259,"PHASE3":1261,"PHASE4":1272,"NA":1274},{"trials":1256,"activeCount":98},[],{"trials":1258,"activeCount":98},[],{"trials":1260,"activeCount":98},[],{"trials":1262,"activeCount":98},[1263],{"nctId":1264,"briefTitle":1265,"status":937,"phases":1266,"primaryCompletion":1267,"completion":1267,"start":1268,"enrollment":277,"conditions":1269,"interventions":1271},"NCT01318590","Prospective Study on Endoscopic Ultrasound (EUS) Celiac Bloc Efficacy in Chronic Pancreatitis",[89],"2019-06-14","2011-11-18",[1270],"Pancreatitis, Chronic",[1253],{"trials":1273,"activeCount":98},[],{"trials":1275,"activeCount":98},[],{"intervention":1277,"totalTrials":94,"cells":1278},"Dexmedetomidine",{"EARLY_PHASE1":1279,"PHASE1":1281,"PHASE2":1283,"PHASE3":1285,"PHASE4":1298,"NA":1300},{"trials":1280,"activeCount":98},[],{"trials":1282,"activeCount":98},[],{"trials":1284,"activeCount":98},[],{"trials":1286,"activeCount":98},[1287],{"nctId":1288,"briefTitle":1289,"status":286,"phases":1290,"primaryCompletion":1291,"completion":1292,"start":1293,"enrollment":398,"conditions":1294,"interventions":1296},"NCT03115047","Shivering Treatment After Cesarean Delivery: Meperidine vs. Dexmedetomidine",[89],"2020-08-19","2020-08-20","2017-05-07",[1295],"Cesarean Section Complications",[1277,1297],"Meperidine",{"trials":1299,"activeCount":98},[],{"trials":1301,"activeCount":98},[],{"intervention":1297,"totalTrials":94,"cells":1303},{"EARLY_PHASE1":1304,"PHASE1":1306,"PHASE2":1308,"PHASE3":1310,"PHASE4":1316,"NA":1318},{"trials":1305,"activeCount":98},[],{"trials":1307,"activeCount":98},[],{"trials":1309,"activeCount":98},[],{"trials":1311,"activeCount":98},[1312],{"nctId":1288,"briefTitle":1289,"status":286,"phases":1313,"primaryCompletion":1291,"completion":1292,"start":1293,"enrollment":398,"conditions":1314,"interventions":1315},[89],[1295],[1277,1297],{"trials":1317,"activeCount":98},[],{"trials":1319,"activeCount":98},[],{"intervention":1321,"totalTrials":94,"cells":1322},"cannabis 0 mg, placebo",{"EARLY_PHASE1":1323,"PHASE1":1325,"PHASE2":1327,"PHASE3":1342,"PHASE4":1344,"NA":1346},{"trials":1324,"activeCount":98},[],{"trials":1326,"activeCount":98},[],{"trials":1328,"activeCount":98},[1329],{"nctId":1330,"briefTitle":1331,"status":286,"phases":1332,"primaryCompletion":1333,"completion":1333,"start":1334,"enrollment":1335,"conditions":1336,"interventions":1337},"NCT05407285","A Study of Ingested Cannabidiol in Healthy Occasional Cannabis Users",[87,88],"2023-11-14","2022-07-22",70,[347],[1321,1338,1339,1340,1341],"Cannabis 20 mg,","Cannabis 50 mg","Cannabis 100 mg","Cannabis 200 mg",{"trials":1343,"activeCount":98},[],{"trials":1345,"activeCount":98},[],{"trials":1347,"activeCount":98},[],{"intervention":1338,"totalTrials":94,"cells":1349},{"EARLY_PHASE1":1350,"PHASE1":1352,"PHASE2":1354,"PHASE3":1360,"PHASE4":1362,"NA":1364},{"trials":1351,"activeCount":98},[],{"trials":1353,"activeCount":98},[],{"trials":1355,"activeCount":98},[1356],{"nctId":1330,"briefTitle":1331,"status":286,"phases":1357,"primaryCompletion":1333,"completion":1333,"start":1334,"enrollment":1335,"conditions":1358,"interventions":1359},[87,88],[347],[1321,1338,1339,1340,1341],{"trials":1361,"activeCount":98},[],{"trials":1363,"activeCount":98},[],{"trials":1365,"activeCount":98},[],{"intervention":1339,"totalTrials":94,"cells":1367},{"EARLY_PHASE1":1368,"PHASE1":1370,"PHASE2":1372,"PHASE3":1378,"PHASE4":1380,"NA":1382},{"trials":1369,"activeCount":98},[],{"trials":1371,"activeCount":98},[],{"trials":1373,"activeCount":98},[1374],{"nctId":1330,"briefTitle":1331,"status":286,"phases":1375,"primaryCompletion":1333,"completion":1333,"start":1334,"enrollment":1335,"conditions":1376,"interventions":1377},[87,88],[347],[1321,1338,1339,1340,1341],{"trials":1379,"activeCount":98},[],{"trials":1381,"activeCount":98},[],{"trials":1383,"activeCount":98},[],{"intervention":1340,"totalTrials":94,"cells":1385},{"EARLY_PHASE1":1386,"PHASE1":1388,"PHASE2":1390,"PHASE3":1396,"PHASE4":1398,"NA":1400},{"trials":1387,"activeCount":98},[],{"trials":1389,"activeCount":98},[],{"trials":1391,"activeCount":98},[1392],{"nctId":1330,"briefTitle":1331,"status":286,"phases":1393,"primaryCompletion":1333,"completion":1333,"start":1334,"enrollment":1335,"conditions":1394,"interventions":1395},[87,88],[347],[1321,1338,1339,1340,1341],{"trials":1397,"activeCount":98},[],{"trials":1399,"activeCount":98},[],{"trials":1401,"activeCount":98},[],{"intervention":1341,"totalTrials":94,"cells":1403},{"EARLY_PHASE1":1404,"PHASE1":1406,"PHASE2":1408,"PHASE3":1414,"PHASE4":1416,"NA":1418},{"trials":1405,"activeCount":98},[],{"trials":1407,"activeCount":98},[],{"trials":1409,"activeCount":98},[1410],{"nctId":1330,"briefTitle":1331,"status":286,"phases":1411,"primaryCompletion":1333,"completion":1333,"start":1334,"enrollment":1335,"conditions":1412,"interventions":1413},[87,88],[347],[1321,1338,1339,1340,1341],{"trials":1415,"activeCount":98},[],{"trials":1417,"activeCount":98},[],{"trials":1419,"activeCount":98},[],{"intervention":1421,"totalTrials":94,"cells":1422},"Liraglutide-metformin vs insulin-metformin",{"EARLY_PHASE1":1423,"PHASE1":1425,"PHASE2":1427,"PHASE3":1439,"PHASE4":1441,"NA":1443},{"trials":1424,"activeCount":98},[],{"trials":1426,"activeCount":98},[],{"trials":1428,"activeCount":98},[1429],{"nctId":1430,"briefTitle":1431,"status":286,"phases":1432,"primaryCompletion":1433,"completion":1433,"start":1434,"enrollment":474,"conditions":1435,"interventions":1438},"NCT01399645","Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes",[88],"2014-06","2011-05",[1436,1437,1136],"Nonalcoholic Fatty Liver Disease","Nonalcoholic Steatohepatitis",[1421],{"trials":1440,"activeCount":98},[],{"trials":1442,"activeCount":98},[],{"trials":1444,"activeCount":98},[],{"intervention":1446,"totalTrials":94,"cells":1447},"tramadol",{"EARLY_PHASE1":1448,"PHASE1":1450,"PHASE2":1452,"PHASE3":1465,"PHASE4":1467,"NA":1469},{"trials":1449,"activeCount":98},[],{"trials":1451,"activeCount":98},[],{"trials":1453,"activeCount":98},[1454],{"nctId":1455,"briefTitle":1456,"status":937,"phases":1457,"primaryCompletion":1458,"completion":1458,"start":1459,"enrollment":345,"conditions":1460,"interventions":1464},"NCT02247648","Efficacy of Extended-release, Once Daily Tramadol for Post Operative Analgesia in Shoulder Arthroscopy",[88],"2017-12","2013-06",[21,1461,1462,1463],"Vertigo","Nausea","Pruritus",[1446],{"trials":1466,"activeCount":98},[],{"trials":1468,"activeCount":98},[],{"trials":1470,"activeCount":98},[],{"intervention":1472,"totalTrials":94,"cells":1473},"intra-rectal Botulinum toxin A",{"EARLY_PHASE1":1474,"PHASE1":1476,"PHASE2":1478,"PHASE3":1491,"PHASE4":1493,"NA":1495},{"trials":1475,"activeCount":98},[],{"trials":1477,"activeCount":98},[],{"trials":1479,"activeCount":98},[1480],{"nctId":1481,"briefTitle":1482,"status":286,"phases":1483,"primaryCompletion":1016,"completion":1484,"start":1485,"enrollment":1486,"conditions":1487,"interventions":1490},"NCT01589471","The Value of Botox-A for Management of Low Anterior Resection Syndrome",[88],"2015-11","2012-05",23,[1488,1489],"Low Anterior Resection Syndrome","Rectal Cancer",[1472],{"trials":1492,"activeCount":98},[],{"trials":1494,"activeCount":98},[],{"trials":1496,"activeCount":98},[],{"intervention":1498,"totalTrials":94,"cells":1499},"SIMVASTATIN",{"EARLY_PHASE1":1500,"PHASE1":1502,"PHASE2":1504,"PHASE3":1515,"PHASE4":1517,"NA":1519},{"trials":1501,"activeCount":98},[],{"trials":1503,"activeCount":98},[],{"trials":1505,"activeCount":98},[1506],{"nctId":1507,"briefTitle":1508,"status":937,"phases":1509,"primaryCompletion":1510,"completion":1510,"start":1511,"enrollment":22,"conditions":1512,"interventions":1514},"NCT01771198","Efficacy Study of SIMVASTATIN to Treat Chronic Rhinosinusitis After Failure of Optimal Treatment",[88],"2015-07","2012-08",[1513],"Rhinosinusitis",[1498],{"trials":1516,"activeCount":98},[],{"trials":1518,"activeCount":98},[],{"trials":1520,"activeCount":98},[],{"intervention":1522,"totalTrials":94,"cells":1523},"Cabazitaxel plus prednisone",{"EARLY_PHASE1":1524,"PHASE1":1526,"PHASE2":1528,"PHASE3":1540,"PHASE4":1542,"NA":1544},{"trials":1525,"activeCount":98},[],{"trials":1527,"activeCount":98},[],{"trials":1529,"activeCount":98},[1530],{"nctId":1531,"briefTitle":1532,"status":937,"phases":1533,"primaryCompletion":496,"completion":496,"start":1534,"enrollment":1535,"conditions":1536,"interventions":1538},"NCT03764540","Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide",[88],"2019-04-01",57,[1537],"Metastatic Prostate Cancer",[1522,1539],"Docetaxel plus prednisone",{"trials":1541,"activeCount":98},[],{"trials":1543,"activeCount":98},[],{"trials":1545,"activeCount":98},[],{"intervention":1539,"totalTrials":94,"cells":1547},{"EARLY_PHASE1":1548,"PHASE1":1550,"PHASE2":1552,"PHASE3":1558,"PHASE4":1560,"NA":1562},{"trials":1549,"activeCount":98},[],{"trials":1551,"activeCount":98},[],{"trials":1553,"activeCount":98},[1554],{"nctId":1531,"briefTitle":1532,"status":937,"phases":1555,"primaryCompletion":496,"completion":496,"start":1534,"enrollment":1535,"conditions":1556,"interventions":1557},[88],[1537],[1522,1539],{"trials":1559,"activeCount":98},[],{"trials":1561,"activeCount":98},[],{"trials":1563,"activeCount":98},[],{"intervention":1565,"totalTrials":94,"cells":1566},"Nab-Paclitaxel",{"EARLY_PHASE1":1567,"PHASE1":1569,"PHASE2":1571,"PHASE3":1584,"PHASE4":1586,"NA":1588},{"trials":1568,"activeCount":98},[],{"trials":1570,"activeCount":98},[],{"trials":1572,"activeCount":98},[1573],{"nctId":1574,"briefTitle":1575,"status":286,"phases":1576,"primaryCompletion":1577,"completion":1578,"start":1579,"enrollment":1580,"conditions":1581,"interventions":1582},"NCT02733250","Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer",[87,88],"2019-04-13","2019-12-13","2017-03-13",10,[15],[1583,1565],"Pembrolizumab",{"trials":1585,"activeCount":98},[],{"trials":1587,"activeCount":98},[],{"trials":1589,"activeCount":98},[],{"intervention":1591,"totalTrials":94,"cells":1592},"Ure-Na",{"EARLY_PHASE1":1593,"PHASE1":1595,"PHASE2":1597,"PHASE3":1608,"PHASE4":1610,"NA":1612},{"trials":1594,"activeCount":98},[],{"trials":1596,"activeCount":98},[],{"trials":1598,"activeCount":98},[1599],{"nctId":1600,"briefTitle":1601,"status":1013,"phases":1602,"primaryCompletion":111,"completion":1603,"start":1604,"enrollment":98,"conditions":1605,"interventions":1607},"NCT04727606","Research Project: Pilot Study on Oral Urea Use in Patients at High Risk of Kidney Stone Recurrence",[88],"2024-06-15","2023-01-15",[1606],"Kidney Stone",[1591],{"trials":1609,"activeCount":98},[],{"trials":1611,"activeCount":98},[],{"trials":1613,"activeCount":98},[],{"intervention":1615,"totalTrials":94,"cells":1616},"Peg-interferon alpha-2a, Ribavirin",{"EARLY_PHASE1":1617,"PHASE1":1619,"PHASE2":1621,"PHASE3":1633,"PHASE4":1635,"NA":1637},{"trials":1618,"activeCount":98},[],{"trials":1620,"activeCount":98},[],{"trials":1622,"activeCount":98},[1623],{"nctId":1624,"briefTitle":1625,"status":286,"phases":1626,"primaryCompletion":1627,"completion":1627,"start":1628,"enrollment":1629,"conditions":1630,"interventions":1632},"NCT01289496","Ribavirin Dose Optimization for the Treatment of Hepatitis C",[88],"2013-08","2011-02",13,[1631],"Chronic Hepatitis C",[1615],{"trials":1634,"activeCount":98},[],{"trials":1636,"activeCount":98},[],{"trials":1638,"activeCount":98},[],{"intervention":1640,"totalTrials":94,"cells":1641},"Cannabidiol",{"EARLY_PHASE1":1642,"PHASE1":1644,"PHASE2":1646,"PHASE3":1660,"PHASE4":1662,"NA":1664},{"trials":1643,"activeCount":98},[],{"trials":1645,"activeCount":98},[],{"trials":1647,"activeCount":98},[1648],{"nctId":1649,"briefTitle":1650,"status":286,"phases":1651,"primaryCompletion":1652,"completion":1652,"start":1653,"enrollment":1654,"conditions":1655,"interventions":1659},"NCT02559167","Cannabidiol and Cocaine Craving\u002FDependence",[88],"2019-08-16","2016-07-01",79,[1656,1657,1658],"Substance Use Disorder","Cocaine Dependence","Withdrawal From Addictive Substance; Detoxification",[1640],{"trials":1661,"activeCount":98},[],{"trials":1663,"activeCount":98},[],{"trials":1665,"activeCount":98},[],{"intervention":1667,"totalTrials":94,"cells":1668},"drug administration",{"EARLY_PHASE1":1669,"PHASE1":1671,"PHASE2":1673,"PHASE3":1683,"PHASE4":1685,"NA":1687},{"trials":1670,"activeCount":98},[],{"trials":1672,"activeCount":98},[],{"trials":1674,"activeCount":98},[1675],{"nctId":1676,"briefTitle":1677,"status":1013,"phases":1678,"primaryCompletion":1458,"completion":1458,"start":1679,"enrollment":98,"conditions":1680,"interventions":1682},"NCT02952196","Cannabioids as a New Intervention for Amphetamine Dependence",[88],"2016-11",[1681],"Amphetamine Addiction",[1667],{"trials":1684,"activeCount":98},[],{"trials":1686,"activeCount":98},[],{"trials":1688,"activeCount":98},[],{"intervention":1690,"totalTrials":94,"cells":1691},"Nivolumab",{"EARLY_PHASE1":1692,"PHASE1":1694,"PHASE2":1696,"PHASE3":1712,"PHASE4":1714,"NA":1716},{"trials":1693,"activeCount":98},[],{"trials":1695,"activeCount":98},[],{"trials":1697,"activeCount":98},[1698],{"nctId":1699,"briefTitle":1700,"status":286,"phases":1701,"primaryCompletion":1702,"completion":1703,"start":1704,"enrollment":1705,"conditions":1706,"interventions":1711},"NCT02978404","Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases",[88],"2021-01-31","2023-12-31","2017-06-02",26,[1707,449,1708,1709,1710],"Clear-Cell Metastatic Renal Cell Carcinoma","Brain Metastases, Adult","Small Cell Lung Cancer","Melanoma",[1690],{"trials":1713,"activeCount":98},[],{"trials":1715,"activeCount":98},[],{"trials":1717,"activeCount":98},[],{"intervention":1719,"totalTrials":94,"cells":1720},"Maraviroc",{"EARLY_PHASE1":1721,"PHASE1":1723,"PHASE2":1737,"PHASE3":1739,"PHASE4":1741,"NA":1743},{"trials":1722,"activeCount":98},[],{"trials":1724,"activeCount":98},[1725],{"nctId":1726,"briefTitle":1727,"status":286,"phases":1728,"primaryCompletion":1729,"completion":1730,"start":1731,"enrollment":1732,"conditions":1733,"interventions":1735},"NCT01627717","The Effects of the Direct Acting Antiviral Agent Boceprevir on the Pharmacokinetics of Maraviroc in Healthy Volunteers",[87],"2013-04","2014-02","2012-06",11,[1734],"Healthy",[1719,1736],"Maraviroc and boceprevir",{"trials":1738,"activeCount":98},[],{"trials":1740,"activeCount":98},[],{"trials":1742,"activeCount":98},[],{"trials":1744,"activeCount":98},[],{"intervention":1736,"totalTrials":94,"cells":1746},{"EARLY_PHASE1":1747,"PHASE1":1749,"PHASE2":1755,"PHASE3":1757,"PHASE4":1759,"NA":1761},{"trials":1748,"activeCount":98},[],{"trials":1750,"activeCount":98},[1751],{"nctId":1726,"briefTitle":1727,"status":286,"phases":1752,"primaryCompletion":1729,"completion":1730,"start":1731,"enrollment":1732,"conditions":1753,"interventions":1754},[87],[1734],[1719,1736],{"trials":1756,"activeCount":98},[],{"trials":1758,"activeCount":98},[],{"trials":1760,"activeCount":98},[],{"trials":1762,"activeCount":98},[],{"intervention":1764,"totalTrials":94,"cells":1765},"Rosuvastatin, Pantoprazole",{"EARLY_PHASE1":1766,"PHASE1":1768,"PHASE2":1779,"PHASE3":1781,"PHASE4":1783,"NA":1785},{"trials":1767,"activeCount":98},[],{"trials":1769,"activeCount":98},[1770],{"nctId":1771,"briefTitle":1772,"status":286,"phases":1773,"primaryCompletion":1774,"completion":1774,"start":1775,"enrollment":16,"conditions":1776,"interventions":1778},"NCT01146483","Drug-drug Interaction Study in Healthy Male Volunteers Following the Administration of Pantoprazole and Rosuvastatin",[87],"2011-12","2010-04",[1777],"Drug Interaction Potentiation",[1764],{"trials":1780,"activeCount":98},[],{"trials":1782,"activeCount":98},[],{"trials":1784,"activeCount":98},[],{"trials":1786,"activeCount":98},[],{"intervention":1788,"totalTrials":94,"cells":1789},"Camu Camu Capsules (Camu Camu powder encapsulated (500mg each) + ICI",{"EARLY_PHASE1":1790,"PHASE1":1792,"PHASE2":1806,"PHASE3":1808,"PHASE4":1810,"NA":1812},{"trials":1791,"activeCount":98},[],{"trials":1793,"activeCount":98},[1794],{"nctId":1795,"briefTitle":1796,"status":286,"phases":1797,"primaryCompletion":1798,"completion":1798,"start":1799,"enrollment":447,"conditions":1800,"interventions":1805},"NCT05303493","Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma",[87],"2025-07-15","2022-06-29",[1801,1802,1803,1804],"NSCLC Stage IV","Melanoma Stage IV","Unresectable Melanoma","Advanced Non-Small Cell Lung Cancer",[1788],{"trials":1807,"activeCount":98},[],{"trials":1809,"activeCount":98},[],{"trials":1811,"activeCount":98},[],{"trials":1813,"activeCount":98},[],{"intervention":1815,"totalTrials":94,"cells":1816},"Mirtazapine 7.5 MG Oral Tablet once daily at bedtime",{"EARLY_PHASE1":1817,"PHASE1":1819,"PHASE2":1831,"PHASE3":1833,"PHASE4":1835,"NA":1837},{"trials":1818,"activeCount":98},[],{"trials":1820,"activeCount":98},[1821],{"nctId":1822,"briefTitle":1823,"status":286,"phases":1824,"primaryCompletion":1825,"completion":1825,"start":1826,"enrollment":1827,"conditions":1828,"interventions":1830},"NCT05247697","Mirtazapine for Chronic Insomnia in Older Adults",[87],"2024-07-30","2022-10-01",60,[1829],"Chronic Insomnia",[1815],{"trials":1832,"activeCount":98},[],{"trials":1834,"activeCount":98},[],{"trials":1836,"activeCount":98},[],{"trials":1838,"activeCount":98},[],{"intervention":1840,"totalTrials":941,"cells":1841},"Remifentanil",{"EARLY_PHASE1":1842,"PHASE1":1844,"PHASE2":1846,"PHASE3":1848,"PHASE4":1850,"NA":1852},{"trials":1843,"activeCount":98},[],{"trials":1845,"activeCount":98},[],{"trials":1847,"activeCount":98},[],{"trials":1849,"activeCount":98},[],{"trials":1851,"activeCount":98},[],{"trials":1853,"activeCount":98},[1854,1865,1875],{"nctId":1855,"briefTitle":1856,"status":286,"phases":1857,"primaryCompletion":1858,"completion":1858,"start":1859,"enrollment":1860,"conditions":1861,"interventions":1863},"NCT01451840","Efficacy of Alkalinized Lidocaine Compared to Remifentanil on the Incidence of Coughing During Emergence of Anesthesia",[91],"2012-10","2012-01",85,[1862,33],"Cough",[1840,1864],"Alkalinized lidocaine",{"nctId":1866,"briefTitle":1867,"status":286,"phases":1868,"primaryCompletion":1244,"completion":1869,"start":1775,"enrollment":1870,"conditions":1871,"interventions":1873},"NCT01026129","Efficacy of Remifentanil Compared to Lidocaine on the Incidence of Coughing During Emergence of Anesthesia",[91],"2010-07",93,[1862,33,1872],"Extubation",[1840,1840,1874],"lidocaine",{"nctId":1876,"briefTitle":1877,"status":286,"phases":1878,"primaryCompletion":1858,"completion":1858,"start":1879,"enrollment":1880,"conditions":1881,"interventions":1882},"NCT01489072","Efficacy of Two Bolus Doses of Remifentanil on the Incidence of Coughing During Emergence of Anesthesia",[91],"2012-04",180,[1862,33],[1840,1840],{"intervention":1864,"totalTrials":277,"cells":1884},{"EARLY_PHASE1":1885,"PHASE1":1887,"PHASE2":1889,"PHASE3":1891,"PHASE4":1893,"NA":1895},{"trials":1886,"activeCount":98},[],{"trials":1888,"activeCount":98},[],{"trials":1890,"activeCount":98},[],{"trials":1892,"activeCount":98},[],{"trials":1894,"activeCount":98},[],{"trials":1896,"activeCount":98},[1897,1907],{"nctId":1898,"briefTitle":1899,"status":286,"phases":1900,"primaryCompletion":1901,"completion":1901,"start":1902,"enrollment":1903,"conditions":1904,"interventions":1905},"NCT01715688","Efficacy of Alkalinized Lidocaine in the Endotracheal Tube Cuff on the Incidence of Coughing During Emergence",[91],"2014-04","2013-01",200,[1862,33],[1864,1906],"Saline",{"nctId":1855,"briefTitle":1856,"status":286,"phases":1908,"primaryCompletion":1858,"completion":1858,"start":1859,"enrollment":1860,"conditions":1909,"interventions":1910},[91],[1862,33],[1840,1864],{"intervention":1912,"totalTrials":277,"cells":1913},"Dexamethasone",{"EARLY_PHASE1":1914,"PHASE1":1916,"PHASE2":1918,"PHASE3":1920,"PHASE4":1922,"NA":1924},{"trials":1915,"activeCount":98},[],{"trials":1917,"activeCount":98},[],{"trials":1919,"activeCount":98},[],{"trials":1921,"activeCount":98},[],{"trials":1923,"activeCount":98},[],{"trials":1925,"activeCount":98},[1926,1938],{"nctId":1927,"briefTitle":1928,"status":286,"phases":1929,"primaryCompletion":1930,"completion":1930,"start":1931,"enrollment":1827,"conditions":1932,"interventions":1936},"NCT03078062","Impact of Dexamethasone on the Duration of Sensory and Motor Block Following Spinal Anesthesia",[91],"2017-10-26","2017-05-26",[1933,1934,1935],"Spinal Anesthesia","Prolonged Sensory Block","Prolonged Motor Block",[1912,1937],"Normal saline",{"nctId":1939,"briefTitle":1940,"status":1013,"phases":1941,"primaryCompletion":1942,"completion":1943,"start":1944,"enrollment":98,"conditions":1945,"interventions":1948},"NCT03256149","High Dose Steroids for Dysphagia",[91],"2018-11","2019-02","2015-03-24",[1946,1947],"Dysphagia","Cervical Spine Disease",[1912],{"intervention":1950,"totalTrials":277,"cells":1951},"Heparin",{"EARLY_PHASE1":1952,"PHASE1":1954,"PHASE2":1956,"PHASE3":1958,"PHASE4":1960,"NA":1962},{"trials":1953,"activeCount":98},[],{"trials":1955,"activeCount":98},[],{"trials":1957,"activeCount":98},[],{"trials":1959,"activeCount":98},[],{"trials":1961,"activeCount":98},[],{"trials":1963,"activeCount":98},[1964,1972],{"nctId":1965,"briefTitle":1966,"status":286,"phases":1967,"primaryCompletion":1968,"completion":1968,"start":1015,"enrollment":11,"conditions":1969,"interventions":1971},"NCT02477072","Optimized Heparin Regimen in Vascular Surgery",[91],"2016-01",[1970],"Peripheral Revascularisation",[1950],{"nctId":1973,"briefTitle":1974,"status":286,"phases":1975,"primaryCompletion":1976,"completion":1976,"start":1977,"enrollment":1978,"conditions":1979,"interventions":1981},"NCT01855516","Partial Thromboplastin Time After 72 Hours of Antithrombotic Prophylaxis Using Unfractionated Heparin",[91],"2015-12","2013-09",83,[1980],"Thrombosis",[1950],{"intervention":1583,"totalTrials":277,"cells":1983},{"EARLY_PHASE1":1984,"PHASE1":1986,"PHASE2":1988,"PHASE3":1994,"PHASE4":1996,"NA":1998},{"trials":1985,"activeCount":98},[],{"trials":1987,"activeCount":98},[],{"trials":1989,"activeCount":98},[1990],{"nctId":1574,"briefTitle":1575,"status":286,"phases":1991,"primaryCompletion":1577,"completion":1578,"start":1579,"enrollment":1580,"conditions":1992,"interventions":1993},[87,88],[15],[1583,1565],{"trials":1995,"activeCount":98},[],{"trials":1997,"activeCount":98},[],{"trials":1999,"activeCount":98},[2000],{"nctId":2001,"briefTitle":2002,"status":286,"phases":2003,"primaryCompletion":2004,"completion":2004,"start":2005,"enrollment":2006,"conditions":2007,"interventions":2010},"NCT04793815","Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE)",[91],"2023-06-27","2021-05-01",15,[2008,2009],"Non-small Cell Lung Cancer Metastatic","Cryotherapy Effect",[1583],{"intervention":2012,"totalTrials":94,"cells":2013},"Mannitol",{"EARLY_PHASE1":2014,"PHASE1":2016,"PHASE2":2018,"PHASE3":2020,"PHASE4":2022,"NA":2024},{"trials":2015,"activeCount":98},[],{"trials":2017,"activeCount":98},[],{"trials":2019,"activeCount":98},[],{"trials":2021,"activeCount":98},[],{"trials":2023,"activeCount":98},[],{"trials":2025,"activeCount":98},[2026],{"nctId":2027,"briefTitle":2028,"status":286,"phases":2029,"primaryCompletion":1434,"completion":1434,"start":1775,"enrollment":398,"conditions":2030,"interventions":2033},"NCT01048684","Comparison of Two Doses of Mannitol on Brain Relaxation During Supratentorial Craniotomy",[91],[2031,2032],"Brain Tumor","Intracranial Pressure",[2012,2012],{"intervention":1906,"totalTrials":94,"cells":2035},{"EARLY_PHASE1":2036,"PHASE1":2038,"PHASE2":2040,"PHASE3":2042,"PHASE4":2044,"NA":2046},{"trials":2037,"activeCount":98},[],{"trials":2039,"activeCount":98},[],{"trials":2041,"activeCount":98},[],{"trials":2043,"activeCount":98},[],{"trials":2045,"activeCount":98},[],{"trials":2047,"activeCount":98},[2048],{"nctId":1898,"briefTitle":1899,"status":286,"phases":2049,"primaryCompletion":1901,"completion":1901,"start":1902,"enrollment":1903,"conditions":2050,"interventions":2051},[91],[1862,33],[1864,1906],{"intervention":2053,"totalTrials":94,"cells":2054},"Best standard treatment",{"EARLY_PHASE1":2055,"PHASE1":2057,"PHASE2":2059,"PHASE3":2061,"PHASE4":2063,"NA":2065},{"trials":2056,"activeCount":98},[],{"trials":2058,"activeCount":98},[],{"trials":2060,"activeCount":98},[],{"trials":2062,"activeCount":98},[],{"trials":2064,"activeCount":98},[],{"trials":2066,"activeCount":98},[2067],{"nctId":2068,"briefTitle":2069,"status":2070,"phases":2071,"primaryCompletion":2072,"completion":2073,"start":1902,"enrollment":2074,"conditions":2075,"interventions":2076},"NCT02157532","Endovascular Acute Stroke Intervention Trial - the EASI Trial","SUSPENDED",[91],"2025-01","2026-01",480,[750],[2053],{"intervention":2078,"totalTrials":94,"cells":2079},"Dexamethasone per os",{"EARLY_PHASE1":2080,"PHASE1":2082,"PHASE2":2084,"PHASE3":2086,"PHASE4":2088,"NA":2090},{"trials":2081,"activeCount":98},[],{"trials":2083,"activeCount":98},[],{"trials":2085,"activeCount":98},[],{"trials":2087,"activeCount":98},[],{"trials":2089,"activeCount":98},[],{"trials":2091,"activeCount":98},[2092],{"nctId":2093,"briefTitle":2094,"status":286,"phases":2095,"primaryCompletion":1627,"completion":1627,"start":1156,"enrollment":823,"conditions":2096,"interventions":2098},"NCT01797991","Comparison of Two Regimens of Dexamethasone in the Prevention of Hypersensitivity Reactions to Paclitaxel, a Pilot Study",[91],[2097],"Prevention of Hypersensitivity Reactions to Paclitaxel",[2078,2099],"Dexamethasone IV",{"intervention":2099,"totalTrials":94,"cells":2101},{"EARLY_PHASE1":2102,"PHASE1":2104,"PHASE2":2106,"PHASE3":2108,"PHASE4":2110,"NA":2112},{"trials":2103,"activeCount":98},[],{"trials":2105,"activeCount":98},[],{"trials":2107,"activeCount":98},[],{"trials":2109,"activeCount":98},[],{"trials":2111,"activeCount":98},[],{"trials":2113,"activeCount":98},[2114],{"nctId":2093,"briefTitle":2094,"status":286,"phases":2115,"primaryCompletion":1627,"completion":1627,"start":1156,"enrollment":823,"conditions":2116,"interventions":2117},[91],[2097],[2078,2099],{"intervention":1937,"totalTrials":94,"cells":2119},{"EARLY_PHASE1":2120,"PHASE1":2122,"PHASE2":2124,"PHASE3":2126,"PHASE4":2128,"NA":2130},{"trials":2121,"activeCount":98},[],{"trials":2123,"activeCount":98},[],{"trials":2125,"activeCount":98},[],{"trials":2127,"activeCount":98},[],{"trials":2129,"activeCount":98},[],{"trials":2131,"activeCount":98},[2132],{"nctId":1927,"briefTitle":1928,"status":286,"phases":2133,"primaryCompletion":1930,"completion":1930,"start":1931,"enrollment":1827,"conditions":2134,"interventions":2135},[91],[1933,1934,1935],[1912,1937],{"intervention":2137,"totalTrials":94,"cells":2138},"Ropivacaine 0.5% Injectable Solution",{"EARLY_PHASE1":2139,"PHASE1":2141,"PHASE2":2143,"PHASE3":2145,"PHASE4":2147,"NA":2149},{"trials":2140,"activeCount":98},[],{"trials":2142,"activeCount":98},[],{"trials":2144,"activeCount":98},[],{"trials":2146,"activeCount":98},[],{"trials":2148,"activeCount":98},[],{"trials":2150,"activeCount":98},[2151],{"nctId":2152,"briefTitle":2153,"status":286,"phases":2154,"primaryCompletion":38,"completion":38,"start":2155,"enrollment":2156,"conditions":2157,"interventions":2159},"NCT04245280","Effectiveness of PENG Block Combined to LFCN Block on the Quality of Recovery After Total Hip Replacement",[91],"2021-05-04",74,[2158,26],"Total Hip Replacement Surgery",[2137,2160],"Saline Solution",{"intervention":2160,"totalTrials":94,"cells":2162},{"EARLY_PHASE1":2163,"PHASE1":2165,"PHASE2":2167,"PHASE3":2169,"PHASE4":2171,"NA":2173},{"trials":2164,"activeCount":98},[],{"trials":2166,"activeCount":98},[],{"trials":2168,"activeCount":98},[],{"trials":2170,"activeCount":98},[],{"trials":2172,"activeCount":98},[],{"trials":2174,"activeCount":98},[2175],{"nctId":2152,"briefTitle":2153,"status":286,"phases":2176,"primaryCompletion":38,"completion":38,"start":2155,"enrollment":2156,"conditions":2177,"interventions":2178},[91],[2158,26],[2137,2160],{"intervention":2180,"totalTrials":94,"cells":2181},"Fentanyl",{"EARLY_PHASE1":2182,"PHASE1":2184,"PHASE2":2186,"PHASE3":2188,"PHASE4":2190,"NA":2192},{"trials":2183,"activeCount":98},[],{"trials":2185,"activeCount":98},[],{"trials":2187,"activeCount":98},[],{"trials":2189,"activeCount":98},[],{"trials":2191,"activeCount":98},[],{"trials":2193,"activeCount":98},[2194],{"nctId":2195,"briefTitle":2196,"status":937,"phases":2197,"primaryCompletion":2198,"completion":2198,"start":1730,"enrollment":2199,"conditions":2200,"interventions":2202},"NCT01984463","Impact of Epidural Morphine on Shoulder Pain Following Thoracotomy.",[91],"2014-05",22,[26,2201],"Shoulder Pain",[2180,2203],"Morphine",{"intervention":2203,"totalTrials":94,"cells":2205},{"EARLY_PHASE1":2206,"PHASE1":2208,"PHASE2":2210,"PHASE3":2212,"PHASE4":2214,"NA":2216},{"trials":2207,"activeCount":98},[],{"trials":2209,"activeCount":98},[],{"trials":2211,"activeCount":98},[],{"trials":2213,"activeCount":98},[],{"trials":2215,"activeCount":98},[],{"trials":2217,"activeCount":98},[2218],{"nctId":2195,"briefTitle":2196,"status":937,"phases":2219,"primaryCompletion":2198,"completion":2198,"start":1730,"enrollment":2199,"conditions":2220,"interventions":2221},[91],[26,2201],[2180,2203],{"intervention":2223,"totalTrials":94,"cells":2224},"Intravenous dose of 0.5 mg\u002Fkg of propofol",{"EARLY_PHASE1":2225,"PHASE1":2227,"PHASE2":2229,"PHASE3":2231,"PHASE4":2233,"NA":2235},{"trials":2226,"activeCount":98},[],{"trials":2228,"activeCount":98},[],{"trials":2230,"activeCount":98},[],{"trials":2232,"activeCount":98},[],{"trials":2234,"activeCount":98},[],{"trials":2236,"activeCount":98},[2237],{"nctId":2238,"briefTitle":2239,"status":286,"phases":2240,"primaryCompletion":1458,"completion":1458,"start":2241,"enrollment":2242,"conditions":2243,"interventions":2246},"NCT02932397","Efficacy of Propofol vs Placebo in the Prevention of Coughing During Emergence of General Anesthesia Under Desflurane",[91],"2016-10",154,[2244,2245],"Elective Surgery","Coughing",[2223,2247],"Intravenous dose of 0.05 mL\u002Fkg of saline solution",{"intervention":2247,"totalTrials":94,"cells":2249},{"EARLY_PHASE1":2250,"PHASE1":2252,"PHASE2":2254,"PHASE3":2256,"PHASE4":2258,"NA":2260},{"trials":2251,"activeCount":98},[],{"trials":2253,"activeCount":98},[],{"trials":2255,"activeCount":98},[],{"trials":2257,"activeCount":98},[],{"trials":2259,"activeCount":98},[],{"trials":2261,"activeCount":98},[2262],{"nctId":2238,"briefTitle":2239,"status":286,"phases":2263,"primaryCompletion":1458,"completion":1458,"start":2241,"enrollment":2242,"conditions":2264,"interventions":2265},[91],[2244,2245],[2223,2247],{"intervention":2267,"totalTrials":94,"cells":2268},"Bupivacaine",{"EARLY_PHASE1":2269,"PHASE1":2271,"PHASE2":2273,"PHASE3":2275,"PHASE4":2277,"NA":2279},{"trials":2270,"activeCount":98},[],{"trials":2272,"activeCount":98},[],{"trials":2274,"activeCount":98},[],{"trials":2276,"activeCount":98},[],{"trials":2278,"activeCount":98},[],{"trials":2280,"activeCount":98},[2281],{"nctId":2282,"briefTitle":2283,"status":937,"phases":2284,"primaryCompletion":1267,"completion":1267,"start":2285,"enrollment":2199,"conditions":2286,"interventions":2288},"NCT02682082","EUS Guided Neurolysis Celiac Block w\u002Fwo Bupivacaine in Patient Being Treated Palliatively for Pancreatic Cancer",[91],"2016-05-27",[2287],"Pancreatic Cancer",[2267],{"intervention":2290,"totalTrials":94,"cells":2291},"Tranexamic Acid",{"EARLY_PHASE1":2292,"PHASE1":2294,"PHASE2":2296,"PHASE3":2298,"PHASE4":2300,"NA":2302},{"trials":2293,"activeCount":98},[],{"trials":2295,"activeCount":98},[],{"trials":2297,"activeCount":98},[],{"trials":2299,"activeCount":98},[],{"trials":2301,"activeCount":98},[],{"trials":2303,"activeCount":98},[2304],{"nctId":2305,"briefTitle":2306,"status":286,"phases":2307,"primaryCompletion":1901,"completion":1901,"start":1040,"enrollment":2308,"conditions":2309,"interventions":2313},"NCT01258010","Impact of Tranexamic Acid on Red Blood Cell Transfusion in Spinal Surgery",[91],99,[2310,2311,2312],"Neurosurgery","Orthopedic Surgery","Red Blood Cell Transfusion",[2290],{"intervention":2315,"totalTrials":94,"cells":2316},"Continuous infusion of bupivacaine",{"EARLY_PHASE1":2317,"PHASE1":2319,"PHASE2":2321,"PHASE3":2323,"PHASE4":2325,"NA":2327},{"trials":2318,"activeCount":98},[],{"trials":2320,"activeCount":98},[],{"trials":2322,"activeCount":98},[],{"trials":2324,"activeCount":98},[],{"trials":2326,"activeCount":98},[],{"trials":2328,"activeCount":98},[2329],{"nctId":2330,"briefTitle":2331,"status":937,"phases":2332,"primaryCompletion":2333,"completion":2334,"start":2335,"enrollment":9,"conditions":2336,"interventions":2337},"NCT02670759","Continuous Thoracic Paravertebral Analgesia for Video-assisted Thoracoscopic Surgery",[91],"2017-09-30","2017-10-01","2016-03",[26],[2315,2338],"Single dose of bupivacaine",{"intervention":2338,"totalTrials":94,"cells":2340},{"EARLY_PHASE1":2341,"PHASE1":2343,"PHASE2":2345,"PHASE3":2347,"PHASE4":2349,"NA":2351},{"trials":2342,"activeCount":98},[],{"trials":2344,"activeCount":98},[],{"trials":2346,"activeCount":98},[],{"trials":2348,"activeCount":98},[],{"trials":2350,"activeCount":98},[],{"trials":2352,"activeCount":98},[2353],{"nctId":2330,"briefTitle":2331,"status":937,"phases":2354,"primaryCompletion":2333,"completion":2334,"start":2335,"enrollment":9,"conditions":2355,"interventions":2356},[91],[26],[2315,2338],{"intervention":2358,"totalTrials":94,"cells":2359},"Teriflunomide",{"EARLY_PHASE1":2360,"PHASE1":2362,"PHASE2":2364,"PHASE3":2366,"PHASE4":2368,"NA":2370},{"trials":2361,"activeCount":98},[],{"trials":2363,"activeCount":98},[],{"trials":2365,"activeCount":98},[],{"trials":2367,"activeCount":98},[],{"trials":2369,"activeCount":98},[],{"trials":2371,"activeCount":98},[2372],{"nctId":2373,"briefTitle":2374,"status":286,"phases":2375,"primaryCompletion":2376,"completion":2377,"start":1484,"enrollment":2378,"conditions":2379,"interventions":2381},"NCT02490982","Teriflunomide Observational Effectiveness Study",[],"2018-12","2021-06-28",106,[2380],"Relapsing Remitting Multiple Sclerosis",[2358],{"intervention":2383,"totalTrials":94,"cells":2384},"Brivaracetam",{"EARLY_PHASE1":2385,"PHASE1":2387,"PHASE2":2389,"PHASE3":2391,"PHASE4":2393,"NA":2395},{"trials":2386,"activeCount":98},[],{"trials":2388,"activeCount":98},[],{"trials":2390,"activeCount":98},[],{"trials":2392,"activeCount":98},[],{"trials":2394,"activeCount":98},[],{"trials":2396,"activeCount":98},[2397],{"nctId":2398,"briefTitle":2399,"status":286,"phases":2400,"primaryCompletion":2401,"completion":2402,"start":2403,"enrollment":2404,"conditions":2405,"interventions":2407},"NCT03517423","Brivaracetam: a Prospective and Multicentre Post-marketing Observational Study",[],"2022-12-01","2023-08-29","2018-10-04",51,[2406],"Epilepsy",[2383],{"intervention":2409,"totalTrials":94,"cells":2410},"Pregabalin",{"EARLY_PHASE1":2411,"PHASE1":2413,"PHASE2":2415,"PHASE3":2417,"PHASE4":2419,"NA":2421},{"trials":2412,"activeCount":98},[],{"trials":2414,"activeCount":98},[],{"trials":2416,"activeCount":98},[],{"trials":2418,"activeCount":98},[],{"trials":2420,"activeCount":98},[],{"trials":2422,"activeCount":98},[2423],{"nctId":2424,"briefTitle":2425,"status":286,"phases":2426,"primaryCompletion":1879,"completion":1879,"start":1244,"enrollment":2427,"conditions":2428,"interventions":2430},"NCT00967135","Efficacy of Perioperative Pregabalin in Reducing the Incidence of Chronic Neuropathic Pain and Postthoracotomy Syndrome.",[91],110,[2429],"Neuropathic Pain",[2409],{"intervention":2432,"totalTrials":94,"cells":2433},"Temozolomide",{"EARLY_PHASE1":2434,"PHASE1":2436,"PHASE2":2438,"PHASE3":2440,"PHASE4":2442,"NA":2444},{"trials":2435,"activeCount":98},[],{"trials":2437,"activeCount":98},[],{"trials":2439,"activeCount":98},[],{"trials":2441,"activeCount":98},[],{"trials":2443,"activeCount":98},[],{"trials":2445,"activeCount":98},[2446],{"nctId":2447,"briefTitle":2448,"status":1013,"phases":2449,"primaryCompletion":2450,"completion":2450,"start":2451,"enrollment":98,"conditions":2452,"interventions":2456},"NCT00943462","Study of 18F-FEC for Positron Emission Tomography-Computed Tomography (PET-CT) Imaging of GBM",[],"2011-06","2009-06",[2453,2454,2455],"Astrocytoma, Grade IV","Giant Cell Glioblastoma","Glioblastoma Multiforme",[2432],{"intervention":2458,"totalTrials":94,"cells":2459},"Variation of heparin dose",{"EARLY_PHASE1":2460,"PHASE1":2462,"PHASE2":2464,"PHASE3":2466,"PHASE4":2468,"NA":2470},{"trials":2461,"activeCount":98},[],{"trials":2463,"activeCount":98},[],{"trials":2465,"activeCount":98},[],{"trials":2467,"activeCount":98},[],{"trials":2469,"activeCount":98},[],{"trials":2471,"activeCount":98},[2472],{"nctId":2473,"briefTitle":2474,"status":286,"phases":2475,"primaryCompletion":1731,"completion":1731,"start":1775,"enrollment":2476,"conditions":2477,"interventions":2478},"NCT01070875","Partial Thromboplastin Time During the First 24 Hours of Antithrombotic Prophylaxis Using Unfractionated Heparin (UFH)",[91],53,[1980],[2458,2458],{"intervention":1874,"totalTrials":94,"cells":2480},{"EARLY_PHASE1":2481,"PHASE1":2483,"PHASE2":2485,"PHASE3":2487,"PHASE4":2489,"NA":2491},{"trials":2482,"activeCount":98},[],{"trials":2484,"activeCount":98},[],{"trials":2486,"activeCount":98},[],{"trials":2488,"activeCount":98},[],{"trials":2490,"activeCount":98},[],{"trials":2492,"activeCount":98},[2493],{"nctId":1866,"briefTitle":1867,"status":286,"phases":2494,"primaryCompletion":1244,"completion":1869,"start":1775,"enrollment":1870,"conditions":2495,"interventions":2496},[91],[1862,33,1872],[1840,1840,1874]]